Optimizing β-lactam-containing antibiotic combination therapy for the treatment of Buruli ulcer.

ABSTRACT:

Aims

The current treatment for Buruli ulcer is based on empirical evidence of efficacy. However, there is an opportunity for shortening its duration and improving response rates. Evolving understanding of the pharmacokinetic-pharmacodynamic relationships provides the basis for a stronger dose rationale for antibiotics. In conjunction with modelling and simulation, it is possible to identify dosing regimens with the highest probability of target attainment (PTA). This investigation aims to: (i) assess the dose rationale for a new combination therapy including amoxicillin/clavulanic acid (AMX/CLV) currently in clinical trials; and (ii) compare its performance with alternative dosing regimens including rifampicin, clarithromycin and AMX/CLV.

Methods

In vitro estimates of the mi

SUBMITTER: D'Agate S 

PROVIDER: S-EPMC11671329 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature